Multimarker approach including CRP, sST2 and GDF-15 for prognostic stratification in stable heart failure

Nils Kuster, Fabien Huet, Anne-Marie Dupuy, Mariama Akodad, Pascal Battistella, Audrey Agullo, Florence Leclercq, Eran Kalmanovich, Alexandra Meilhac, Sylvain Aguilhon, Jean-Paul Cristol, Francois Roubille, Nils Kuster, Fabien Huet, Anne-Marie Dupuy, Mariama Akodad, Pascal Battistella, Audrey Agullo, Florence Leclercq, Eran Kalmanovich, Alexandra Meilhac, Sylvain Aguilhon, Jean-Paul Cristol, Francois Roubille

Abstract

Aims: Inflammation and cardiac remodelling are common and synergistic pathways in heart failure (HF). Emerging biomarkers such as soluble suppression of tumorigenicity 2 (sST2) and growth differentiation factor-15 (GDF-15), which are linked to inflammation and fibrosis process, have been proposed as prognosis factors. However, their potential additive values remain poorly investigated.

Methods and results: Here, we aimed at evaluating inflammatory and remodelling biomarkers to predict both short-term and long-term mortality in a population with chronic HF in comparison with other classical clinical or biological markers (i.e. N terminal pro brain natriuretic peptide, hs-cTnT, C-reactive protein) alone or using meta-analysis global group in chronic HF risk score in a cohort of 182 patients followed during 80 months (interquartile range: 12.3-90.0). Proportional hazard assumption does not hold for sST2 and C-reactive protein, and follow-up was split into short term (less than 1 year), midterm (between 1 and 5 years), and long term (after 5 years). In univariate analysis, C-reactive protein and sST2 were predictive of short-term mortality but not of middle term and long term whereas GDF-15 was predictive of short and mid-term but not of long-term mortality. In a multivariate model after adjustment for meta-analysis global group in chronic HF score including the three markers, only sST2 was predictive of short-term mortality (P = 0.0225), and only GDF-15 was predictive of middle term mortality (P = 0.0375). None of the markers was predictive of long-term mortality.

Conclusions: Our results demonstrate that both sST2 and GDF-15 significantly improve the prognosis evaluation of HF patients and suggest that the value of GDF-15 is more sustained overtime and could predict middle term events.

Keywords: Biomarkers; C-reactive protein; GDF-15; Heart failure; Hs-troponin; NT-proBNP; Prognosis; sST2.

Conflict of interest statement

None declared.

© 2020 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology.

Figures

Figure 1
Figure 1
Kaplan–Meier curves for all‐cause mortality based on quartiles of C‐reactive protein, soluble suppression of tumorigenicity 2, and growth differentiation factor‐15.
Figure 2
Figure 2
Test of the proportional hazard assumption of Cox regression for C‐reactive protein, soluble suppression of tumorigenicity 2, and growth differentiation factor‐15. Schoenfeld residuals were computed to test proportional hazard assumption. P values indicate significant correlations between Schoenfeld residuals and time for C‐reactive protein and soluble suppression of tumorigenicity 2 (A–B). This correlation is not significant for growth differentiation factor‐15 (C).
Figure 3
Figure 3
Multivariate Cox model after Akaike's information criterion‐based feature selection. Coloured rectangles indicate biomarker‐associated hazard ratios; each biomarker has been assessed for short‐term, middle‐term, and long‐term prediction of mortality. CRP, C‐reactive protein; GDF‐15, growth differentiation factor‐15; LVEF, left ventricular ejection fraction; MAGGIC, meta‐analysis global group in chronic heart failure; MRA, mineralocorticoid receptor antagonist; sST2, soluble suppression of tumorigenicity 2

References

    1. Van Linthout S, Tschöpe C. Inflammation ‐ cause or consequence of heart failure or both? Curr Heart Fail Rep 2017; 14: 251–265.
    1. Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868–874.
    1. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105: 1135–1143.
    1. Heart Protection Study Collaborative Group , Jonathan Emberson null, Derrick Bennett null, Emma Link null, Sarah Parish null, John Danesh null, Jane Armitage null, Rory Collins null . C‐reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20,536 patients in the Heart Protection Study. Lancet Lond Engl 2011; 377: 469–476.
    1. Van Tassell BW, Abouzaki NA, Oddi Erdle C, Carbone S, Trankle CR, Melchior RD, Turlington JS, Thurber CJ, Christopher S, Dixon DL, Fronk DT, Thomas CS, Rose SW, Buckley LF, Dinarello CA, Biondi‐Zoccai G, Abbate A. Interleukin‐1 blockade in acute decompensated heart failure: a randomized, double‐blinded, placebo‐controlled pilot study. J Cardiovasc Pharmacol 2016; 67: 544–551.
    1. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, Kastelein JJP, Cornel JH, Pais P, Pella D, Genest J, Cifkova R, Lorenzatti A, Forster T, Kobalava Z, Vida‐Simiti L, Flather M, Shimokawa H, Ogawa H, Dellborg M, Rossi PRF, Troquay RPT, Libby P, Glynn RJ, CANTOS Trial Group . Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 2017; 377: 1119–1131.
    1. Dieplinger B, Egger M, Gegenhuber A, Haltmayer M, Mueller T. Analytical and clinical evaluation of a rapid quantitative lateral flow immunoassay for measurement of soluble ST2 in human plasma. Clin Chim Acta Int J Clin Chem 2015; 451: 310–315.
    1. Aimo A, Vergaro G, Passino C, Ripoli A, Ky B, Miller WL, Bayes‐Genis A, Anand I, Januzzi JL, Emdin M. Prognostic value of soluble suppression of tumorigenicity‐2 in chronic heart failure: a meta‐analysis. JACC Heart Fail 2017; 5: 280–286.
    1. Adela R, Banerjee SK. GDF‐15 as a target and biomarker for diabetes and cardiovascular diseases: a translational prospective. J Diabetes Res 2015; 2015: 490842.
    1. Lok SI, Winkens B, Goldschmeding R, van Geffen AJP, Nous FMA, van Kuik J, van der Weide P, Klöpping C, Kirkels JH, Lahpor JR, Doevendans PA, de Jonge N, de Weger RA. Circulating growth differentiation factor‐15 correlates with myocardial fibrosis in patients with non‐ischaemic dilated cardiomyopathy and decreases rapidly after left ventricular assist device support. Eur J Heart Fail 2012; 14: 1249–1256.
    1. Wollert KC, Kempf T, Wallentin L. Growth differentiation factor 15 as a biomarker in cardiovascular disease. Clin Chem 2017; 63: 140–151.
    1. Pocock SJ, Ariti CA, McMurray JJV, Maggioni A, Køber L, Squire IB, Swedberg K, Dobson J, Poppe KK, Whalley GA, Doughty RN. Meta‐analysis global group in chronic heart failure. Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies. Eur Heart J 2013; 34: 1404–1413.
    1. Dupuy AM, Curinier C, Kuster N, Huet F, Leclercq F, Davy JM, Cristol JP, Roubille F. Multi‐marker strategy in heart failure: combination of ST2 and CRP predicts poor outcome. PLoS ONE 2016; 11: e0157159.
    1. Dupuy AM, Kuster N, Curinier C, Huet F, Plawecki M, Solecki K, Roubille F, Cristol JP. Exploring collagen remodeling and regulation as prognosis biomarkers in stable heart failure. Clin Chim Acta Int J Clin Chem 2019; 490: 167–171.
    1. Sartipy U, Dahlström U, Edner M, Lund LH. Predicting survival in heart failure: validation of the MAGGIC heart failure risk score in 51,043 patients from the Swedish heart failure registry. Eur J Heart Fail 2014; 16: 173–179.
    1. Kempf T, von Haehling S, Peter T, Allhoff T, Cicoira M, Doehner W, Ponikowski P, Filippatos GS, Rozentryt P, Drexler H, Anker SD, Wollert KC. Prognostic utility of growth differentiation factor‐15 in patients with chronic heart failure. J Am Coll Cardiol 2007; 50: 1054–1060.
    1. Eggers KM, Kempf T, Wallentin L, Wollert KC, Lind L. Change in growth differentiation factor 15 concentrations over time independently predicts mortality in community‐dwelling elderly individuals. Clin Chem 2013; 59: 1091–1098.
    1. Hagström E, Held C, Stewart RAH, Aylward PE, Budaj A, Cannon CP, Koenig W, Krug‐Gourley S, Mohler ER, Steg PG, Tarka E, Östlund O, White HD, Siegbahn A, Wallentin L, STABILITY Investigators . Growth differentiation factor 15 predicts all‐cause morbidity and mortality in stable coronary heart disease. Clin Chem 2017; 63: 325–333.
    1. Anand IS, Kempf T, Rector TS, Tapken H, Allhoff T, Jantzen F, Kuskowski M, Cohn JN, Drexler H, Wollert KC. Serial measurement of growth‐differentiation factor‐15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure Trial. Circulation 2010; 122: 1387–1395.
    1. Lotierzo M, Dupuy AM, Kalmanovich E, Roubille F, Cristol JP. sST2 as a value‐added biomarker in heart failure. Clin Chim Acta Int J Clin Chem 2020; 501: 120–130.
    1. Najjar E, Faxén UL, Hage C, Donal E, Daubert J‐C, Linde C, Lund LH. ST2 in heart failure with preserved and reduced ejection fraction. Scand Cardiovasc J SCJ 2019; 53: 21–27.
    1. Mueller T, Leitner I, Egger M, Haltmayer M, Dieplinger B. Association of the biomarkers soluble ST2, galectin‐3 and growth‐differentiation factor‐15 with heart failure and other non‐cardiac diseases. Clin Chim Acta Int J Clin Chem 2015; 445: 155–160.
    1. Wu AHB, Wians F, Jaffe A. Biological variation of galectin‐3 and soluble ST2 for chronic heart failure: implication on interpretation of test results. Am Heart J 2013; 165: 995–999.
    1. Wang Y, Zhen C, Wang R, Wang G. Growth‐differentiation factor‐15 predicts adverse cardiac events in patients with acute coronary syndrome: a meta‐analysis. Am J Emerg Med 2019; 37: 1346–1352.
    1. Zeng X, Li L, Wen H, Bi Q. Growth‐differentiation factor 15 as a predictor of mortality in patients with heart failure: a meta‐analysis. J Cardiovasc Med Hagerstown Md 2017; 18: 53–59.
    1. Daniels LB, Bayes‐Genis A. Using ST2 in cardiovascular patients: a review. Future Cardiol 2014; 10: 525–539.
    1. Mueller T, Dieplinger B, Gegenhuber A, Poelz W, Pacher R, Haltmayer M. Increased plasma concentrations of soluble ST2 are predictive for 1‐year mortality in patients with acute destabilized heart failure. Clin Chem 2008; 54: 752–756.
    1. Wang TJ, Wollert KC, Larson MG, Coglianese E, McCabe EL, Cheng S, Ho JE, Fradley MG, Ghorbani A, Xanthakis V, Kempf T, Benjamin EJ, Levy D, Vasan RS, Januzzi JL. Prognostic utility of novel biomarkers of cardiovascular stress: the Framingham Heart Study. Circulation 2012; 126: 1596–1604.
    1. Brown DA, Breit SN, Buring J, Fairlie WD, Bauskin AR, Liu T, Ridker PM. Concentration in plasma of macrophage inhibitory cytokine‐1 and risk of cardiovascular events in women: a nested case‐control study. Lancet Lond Engl 2002; 359: 2159–2163.
    1. Fluschnik N, Ojeda F, Zeller T, Jørgensen T, Kuulasmaa K, Becher PM, Sinning C, Blankenberg S, Westermann D. Predictive value of long‐term changes of growth differentiation factor‐15 over a 27‐year‐period for heart failure and death due to coronary heart disease. PLoS ONE 2018; 13: e0197497.
    1. Eggers KM, Kempf T, Larsson A, Lindahl B, Venge P, Wallentin L, Wollert KC, Lind L. Evaluation of temporal changes in cardiovascular biomarker concentrations improves risk prediction in an elderly population from the community. Clin Chem 2016; 62: 485–493.
    1. Richter B, Koller L, Hohensinner PJ, Zorn G, Brekalo M, Berger R, Mörtl D, Maurer G, Pacher R, Huber K, Wojta J, Hülsmann M, Niessner A. A multi‐biomarker risk score improves prediction of long‐term mortality in patients with advanced heart failure. Int J Cardiol 2013; 168: 1251–1257.
    1. Kakkar R, Lee RT. The IL‐33/ST2 pathway: therapeutic target and novel biomarker. Nat Rev Drug Discov 2008; 7: 827–840.
    1. Briasoulis A, Androulakis E, Christophides T, Tousoulis D. The role of inflammation and cell death in the pathogenesis, progression and treatment of heart failure. Heart Fail Rev 2016; 21: 169–176.
    1. Mildner M, Storka A, Lichtenauer M, Mlitz V, Ghannadan M, Hoetzenecker K, Nickl S, Dome B, Tschachler E, Ankersmit HJ. Primary sources and immunological prerequisites for sST2 secretion in humans. Cardiovasc Res 2010; 87: 769–777.
    1. Paulus WJ, Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol 2013; 62: 263–271.
    1. Nagy AI, Hage C, Merkely B, Donal E, Daubert J‐C, Linde C, Lund LH, Manouras A. Left atrial rather than left ventricular impaired mechanics are associated with the pro‐fibrotic ST2 marker and outcomes in heart failure with preserved ejection fraction. J Intern Med 2018; 283: 380–391.
    1. AbouEzzeddine OF, McKie PM, Dunlay SM, Stevens SR, Felker GM, Borlaug BA, Chen HH, Tracy RP, Braunwald E, Redfield MM. Suppression of tumorigenicity 2 in heart failure with preserved ejection fraction. J Am Heart Assoc 2017; 6: e004382.
    1. Xanthakis V, Enserro DM, Murabito JM, Polak JF, Wollert KC, Januzzi JL, Wang TJ, Tofler G, Vasan RS. Ideal cardiovascular health: associations with biomarkers and subclinical disease and impact on incidence of cardiovascular disease in the Framingham Offspring Study. Circulation 2014; 130: 1676–1683.
    1. Wiklund FE, Bennet AM, Magnusson PKE, Eriksson UK, Lindmark F, Wu L, Yaghoutyfam N, Marquis CP, Stattin P, Pedersen NL, Adami H‐O, Grönberg H, Breit SN, Brown DA. Macrophage inhibitory cytokine‐1 (MIC‐1/GDF15): a new marker of all‐cause mortality. Aging Cell 2010; 9: 1057–1064.
    1. Ho JE, Hwang S‐J, Wollert KC, Larson MG, Cheng S, Kempf T, Vasan RS, Januzzi JL, Wang TJ, Fox CS. Biomarkers of cardiovascular stress and incident chronic kidney disease. Clin Chem 2013; 59: 1613–1620.
    1. Daniels LB, Clopton P, Laughlin GA, Maisel AS, Barrett‐Connor E. Growth‐differentiation factor‐15 is a robust, independent predictor of 11‐year mortality risk in community‐dwelling older adults: the Rancho Bernardo Study. Circulation 2011; 123: 2101–2110.
    1. Bonaca MP, Morrow DA, Braunwald E, Cannon CP, Jiang S, Breher S, Sabatine MS, Kempf T, Wallentin L, Wollert KC. Growth differentiation factor‐15 and risk of recurrent events in patients stabilized after acute coronary syndrome: observations from PROVE IT‐TIMI 22. Arterioscler Thromb Vasc Biol 2011; 31: 203–210.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj